Sudarshan Pharma Industries is under due diligence for acquiring a 9.50% stake in MedTherapy Biotechnology. This includes a 1.50% stake from its promoters. The acquisition aims to enhance its US market presence, with completion expected by March 2027.
Market Samachar is a news aggregator. This article was originally published by mint - markets. Tap the button above to read the full story on their site.